Rescop Opens Offices in UK and Australia
Rescop )Regulatory System Compliance Partners) has opened new offices in the UK and Australia.
Rescop (Regulatory System Compliance Partners) has opened new offices in the UK and Australia. This expansion follows the opening of branches in Belgium and the US last year.
“The move was required to accommodate both our current and future growth in EU and the Asia Pacific area, as we continue to expand our team of Life Sciences and software development experts to meet the increasing demand for our consulting services and software products.”
The company was found in 2005 by Piet Vervoort and Björn Aalbers. Its headquarters is in Den Bosch, The Netherlands, and it now has eight offices. It supplies GxP compliance software and services, and assists in the following areas: system life cycle management; commissioning, qualification and validation; change management; IT Delivery and Support; and training
Read the release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
